Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer

Core Insights - Monopar Therapeutics Inc. has appointed Susan Rodriguez as Chief Commercial and Strategy Officer to lead the company's commercial strategy and infrastructure as it prepares for the New Drug Application submission for ALXN1840, a therapy for Wilson disease, in the first half of 2026 [1][2] Company Overview - Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for unmet medical needs, with a late-stage investigational therapy ALXN1840 for Wilson disease and several radiopharmaceutical programs [3] Leadership Appointment - Susan Rodriguez brings over 30 years of biopharmaceutical leadership experience, having previously served as Chief Operating Officer at Avadel Pharmaceuticals, where she contributed to a $2 billion acquisition [2] - Rodriguez has a proven track record in launching rare disease therapies and building commercial teams, which will be crucial for Monopar as it advances ALXN1840 toward approval [2] Product Development - ALXN1840 is positioned as the first major advancement in Wilson disease treatment in decades, with the company aiming to ensure broad patient access and maximize the therapy's impact [2]